Track topics on Twitter Track topics that are important to you
5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 18.104.22.168 Pipeline Review, H1 2019
5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 22.214.171.124 pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report 5' Nucleotidase Pipeline Review, H1 2019, outlays comprehensive information on the 5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 126.96.36.199 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 188.8.131.52 5Nucleotidase 5NT is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 1, 6 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications NonSmall Cell Lung Cancer, Solid Tumor, Ovarian Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Metastatic Breast Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Kidney Cancer Renal Cell Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Muscle Invasive Bladder Cancer MIBC, NonSmall Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.
Furthermore, this report also reviews key players involved in 5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 184.108.40.206 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 220.127.116.11
The report reviews 5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 18.104.22.168 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in 5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 22.214.171.124 targeted therapeutics and enlists all their major and minor projects
The report assesses 5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 126.96.36.199 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to 5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 188.8.131.52 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for 5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 184.108.40.206
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding 5' Nucleotidase Ecto 5' Nucleotidase or CD73 or NT5E or EC 220.127.116.11 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeNEXT ARTICLE
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...